Form 8-K - Current report:
SEC Accession No. 0001193125-25-146134
Filing Date
2025-06-25
Accepted
2025-06-25 07:10:35
Documents
15
Period of Report
2025-06-25
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d923971d8k.htm   iXBRL 8-K 30246
2 EX-99.1 d923971dex991.htm EX-99.1 20313
6 GRAPHIC g923971dsp06a.jpg GRAPHIC 10784
7 GRAPHIC g923971dsp6.jpg GRAPHIC 10047
  Complete submission text file 0001193125-25-146134.txt   203095

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kymr-20250625.xsd EX-101.SCH 2854
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kymr-20250625_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kymr-20250625_pre.xml EX-101.PRE 11264
17 EXTRACTED XBRL INSTANCE DOCUMENT d923971d8k_htm.xml XML 3646
Mailing Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472
Business Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

EIN.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39460 | Film No.: 251070869
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)